title: Reactive oxidants mediate TNF-alpha-induced leukocyte adhesion to rat mesenteric venular endothelium.
abstract: We investigated the role of reactive oxygen metabolites (ROMs) as potential mediators of tumor necrosis factor-alpha (TNF-alpha)-stimulated neutrophil adhesion to rat mesenteric venules in vivo, using intravital microscopy and fixed whole mount preparations of mesentery. Intraperitoneal injection of TNF-alpha significantly increased leukocyte rolling, adhesion, and emigration in a dose- and time-dependent manner. Leukocyte adhesion and emigration, but not rolling, were significantly attenuated by prior intravenous administration of monoclonal anti-intercellular adhesion molecule-1 (ICAM-1). Rolling leukocyte flux was significantly attenuated by intravenous preadministration of superoxide dismutase (SOD), catalase, or both. Only catalase or SOD plus catalase significantly inhibited leukocyte adhesion. Catalase alone inhibited emigration. Moreover, postadhesive treatment with catalase but not SOD, 4 h after TNF-alpha administration reduced the flux of rolling (but not adherent) leukocytes that had previously increased in response to TNF-alpha. Intragastric allopurinol (50 mg/kg at 3 and 18 h before TNF-alpha administration) or 3 wk of a tungsten-enriched diet substantially inhibited xanthine oxidase activity but had no significant effects on the above parameters of neutrophil dynamics. In parallel experiments using fixed whole mount preparations of the mesoappendix stained specifically for neutrophil esterase, neutrophil adhesion 2 h after TNF-alpha administration was also inhibited by continuous intravenous administration of catalase but not by SOD, intragastric allopurinol, or tungsten diet. These findings suggest that ROMs, apparently not from xanthine oxidase, are important mediators of TNF-alpha-induced upregulation of neutrophil adhesion in rat mesenteric venules.
authors.affiliation: Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-4685, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Morita
authors.forename: M G
authors.initials: MG
authors.lastname: Clemens
authors.forename: L S
authors.initials: LS
authors.lastname: Miller
authors.forename: U
authors.initials: U
authors.lastname: Rangan
authors.forename: S
authors.initials: S
authors.lastname: Kondo
authors.forename: M
authors.initials: M
authors.lastname: Miyasaka
authors.forename: T
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: G B
authors.initials: GB
authors.lastname: Bulkley
mesh_terms: D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002448:Cell Adhesion; D004730:Endothelium, Vascular / Q000502:physiology*; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology; D007962:Leukocytes / Q000187:drug effects* / Q000502:physiology; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism*; D013152:Splanchnic Circulation; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D014699:Venules / Q000502:physiology
chemical_list: D000906:Antibodies; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; D000493:Allopurinol; D010088:Oxidoreductases